

AHCCCS

Pharmacy and Therapeutics Committee Meeting Minutes

October 19, 2016

12:00PM- 5:00 PM

701 E. Jefferson Phoenix, AZ 85034- Gold Room- 3rd Floor

Members Present:

Dan Lindell
Otto Uhrik
Johanna Kowalkis
Robert Marotz
Shawn McMahon
James Hargrave
Lydia Nesemann
Cindy Komar
Kathleen Bryant
Suzanne Campbell
Stephen Chakmakian
Olivia Young

AHCCCS Staff:

Sara Salek
Robin Davis
Suzi Berman
Laura Raymond
Kathy Bashor

Magellan Medicaid Admin:

Doug Brown
Sarah Martinez

Members via teleconference:

Members Absent:

Berkely Olvera
Gloria Abril
Mohamad Ramadan

WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS

1. Dr. Sara Salek called the meeting to order at 12:05 PM and welcomed committee members, staff, and guest presenters.
 - a. P&T Minutes from August 16, 2016 were reviewed with updates noted.
 - i. Motion made by Dan Lindell to approve August 2016 meeting minutes
 - ii. Motion seconded by Kathleen Bryant
 - iii. All committee members voted in favor of approving the minutes
 - iv. No committee members opposed or abstained.
-

AHCCCS and Behavioral Health Drug Lists

SUPPLEMENTAL REBATE CLASS REVIEWS

1. Inhaled Antibiotics
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony: None
 - c. Public Testimony: None

2. Cytokine and CAM Antagonists
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony:
 - i. Michelle Mui: Cimzia-UCB
 - ii. Scott Budsberg: Enbrel-Amgen
 - iii. Laura Hill: Humira-Abbvie
 - iv. Marlies Ozias: Orenzia-BMS
 - v. Carrie Johnson: Otezla-Celgene
 - vi. Rick Smith: Xeljanz-Pfizer
 - c. Public Testimony: None

3. Epinephrine – Self Injected
 - a. Clinical review: Sarah Martinez: Provider Synergies
 - b. Pharma Testimony
 - i. Roger Stephens: EpiPen-Mylan
 - c. Public Testimony: None

4. Growth Hormone
 - a. Clinical review: Sarah Martinez: Provider Synergies

- b. Pharma Testimony:
 - i. Patrick Archer: Genotropin-Pfizer
 - ii. Jignesh Patel: Norditropin-NovoNordisk
- c. Public Testimony: None

5. Long-Acting Narcotic Analgesics

- a. Clinical review: Sarah Martinez: Provider Synergies
- b. Pharma Testimony
 - i. Jerod Downing: Butrans-Purdue Pharma
 - ii. Laurence Ikeda: Embeda-Pfizer
 - iii. Jerod Downing: Hysingla ER- Purdue Pharma
 - iv. Jerod Downing: Oxycontin-Purdue Pharma
- c. Public Testimony: None

6. Bevespi Aerosphere

- a. Clinical review: Sarah Martinez: Provider Synergies
- b. Pharma Testimony: None
- c. Public Testimony: None

7. Makena

- a. Clinical review: Sarah Martinez: Provider Synergies
- b. Pharma Testimony: None
- c. Public Testimony: None

8. Executive Session – Closed to the Public

9. Preferred Drug Recommendation to the AHCCCS Drug List and/or the AHCCCS Behavioral Health Drug List for the following classes.

- a. Committee members voted unanimously to add the following to the AHCCCS Drug list as preferred products. No committee members opposed or abstained.
 - i. Antibiotics, Inhaled
 - 1. Kitabis Pak
 - 2. Bethkis

Grandfathering approved for all current utilization

- b. Committee members voted unanimously to add the following to the AHCCCS Drug list as preferred products. No committee members opposed or abstained.
 - i. Cytokine and CAM Antagonists
 - 1. Enbrel
 - 2. Humira

Grandfathering approved for all current utilization

- c. Committee members voted unanimously to add the following to the AHCCCS Drug list as preferred products. No committee members opposed or abstained.
 - i. Epinephrine, Self-Injected
 - 1. Epinephrine .15mg and .3mg (generic Adrenaclick)
 - 2. Epipen
 - 3. Epipen Jr

Grandfathering not applicable

- d. Committee members voted unanimously to add the following to the AHCCCS Drug list as preferred products. No committee members opposed or abstained.
 - i. Growth Hormone
 - ii. Genotropin
 - iii. Norditropin

Grandfathering not applicable

- e. 11 committee members voted in favor to add the following to the AHCCCS Drug list as preferred products. No Committee members opposed. One committee member abstained.
 - i. Long-Acting Narcotic Analgesics
 - 1. Morphine ER
 - 2. Embeda (morphine ER)
 - 3. Hysingla ER (hydrocodone ER)
 - 4. Butrans (buprenorphine)
 - 5. Fentanyl (12.4, 25, 50, 75, 100mcg) patch
 - 6. Oxycontin (oxycodone ER)

PA required for all long acting opioids beginning 1/1/17

Grandfather using individualized phase-in approach

- f. Committee members voted unanimously to add the following to the AHCCCS Drug list as preferred products. No committee members opposed or abstained.
 - i. Makena* Single Dose and Multiple dose vials.

PA required

Claims must be processed at the pharmacy

Grandfathering not applicable

FOLLOW UP: ORAL ONCOLOGY SUBCOMMITTEE: SUZI BERMAN

- 1. HIV Therapeutic Class and Single Agent Reviews
 - a. Committee met to decide how oncology will be handled as new drugs become available. At this time there is nothing to report as it is a work in progress.

FOLLOW UP: HIV SUBCOMMITTEE: SUZI BERMAN

- 1. HIV Therapeutic Class and Single Agent Reviews
 - a. Subcommittee is currently meeting to discuss HIV class. The committee is currently working on gathering PA criteria and will reconvene to discuss which products should be available with or without a PA on the AHCCCS Drug List.

NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: SUZI BERMAN

- 1. The following new drugs were reviewed for the Non-Supplemental Rebate Class
 - a. Xiidra- Lifitegrast ophthalmic solution
 - i. Recommendation is to not add to the AHCCCS Drug List.
 - b. Zynvryta-Daclizumab
 - i. Recommendation is to not add to the AHCCCS Drug List because it is a third line agent.
 - c. Ocaliva- Obeticholic acid

- i. Recommendation is to not add Ocaliva to the AHCCCS Drug List at this time. AHCCCS will review internally due to prevalence of NAFLD and the high annual cost of the drug. In addition, other agents are expected to be approved in the near future for NAFLD.
 - d. Briviact- Brivaracetam
 - i. Recommendation is to not add this to the AHCCCS Drug List because there are several medications listed on the AHCCCS Drug List for use as augmentation strategies for Epilepsy.
- 2. A vote was taken on the recommendations for the non Supplemental Rebate Class.
 - a. 11 committee members voted in favor of the recommendations.
 - b. No committee members voted against the recommendations
 - c. One committee member abstained

OPIOID 7-DAY QUANTITY LIMITATION- SHANA MALONE, AHCCCS

- 1. AHCCCS is looking at multiple strategies to prevent prescription opioid abuse and misuse as well as decrease the number of deaths associated with opioid misuse. A current issue that has been identified is over-prescribing opioids to opioid naïve individuals. The recommendation by the CDC is to limit new starts in opioid naïve individuals to a 7 day supply.
 - a. In 2015, 2 deaths a day were reported in Arizona due to Opioid prescription overdose.
 - b. Over-prescribing on first-fills is a noted issue. The recommendation would be to limit first fills to up to a 7 day supply, especially for Dental providers and Emergency Departments.
 - c. It is understood that there will be many challenges with operationalizing this policy. Plans would need to discuss lookbacks and PA policy for new starts.
 - d. AHCCCS will be reviewing short acting narcotics for quantity limits in a future meeting.

PILL SPLITTING: DR. CHAKMAKIAN, CMO, UNITED HEALTHCARE

- 1. Dr. Chakmakian would like to get more information and present to the committee at a future date.

AGENDA ITEMS FOR JANUARY 25, 2017 P&T

- 1. The Inhaled Glucocorticoids Drug class will be reviewed at the next P&T Committee meeting which will be held on Wednesday, January 25, 2017.
- 2. Please email Suzi Berman with any agenda items

NEXT MEETING DATES

2017 Meeting Dates:

Wednesday, January 25, 2017

Thursday, April 13, 2017

Tuesday July 18, 2017,

Thursday October 12, 2017

ADJOURNMENT

The meeting adjourned at 3:45 PM.

Minutes recorded by Robin Davis

Suzi Berman, RPh

Suzi Berman, RPh

Director of Pharmacy Services

Date: January 25, 2017